These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 14967451)

  • 21. Targeting the EGFR in neoplasia--more questions than answers.
    Dicker AP; Rodeck U
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):899-902. PubMed ID: 14967449
    [No Abstract]   [Full Text] [Related]  

  • 22. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling.
    Bianco R; Damiano V; Gelardi T; Daniele G; Ciardiello F; Tortora G
    Curr Pharm Des; 2007; 13(33):3358-67. PubMed ID: 18045190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Designer-drugs in tumor treatment].
    Beck C; Kneba M
    Internist (Berl); 2004 Jun; 45 Suppl 1():S38-47. PubMed ID: 15148585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Linking oncogenesis and immune system evasion in acquired resistance to EGFR-targeting antibodies: Lessons from a preclinical model.
    Garrido G; Rabasa A; Sánchez B
    Oncoimmunology; 2013 Dec; 2(12):e26904. PubMed ID: 24498560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A promising anoikis-related prognostic signature predicts prognosis of skin cutaneous melanoma.
    Yue Z; Wang D; Li X
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):17757-17770. PubMed ID: 37930439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The mechanism of action and biodistribution of a novel EGFR/VEGF bispecific fusion protein that exhibited superior antitumor activities.
    Deng L; Wang L; Zhang J; Zhao L; Meng Y; Zheng J; Xu W; Zhu Z; Huang H
    Heliyon; 2023 Jun; 9(6):e16922. PubMed ID: 37484224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination Therapy as a Promising Way to Fight Oral Cancer.
    Silva JPN; Pinto B; Monteiro L; Silva PMA; Bousbaa H
    Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor effects of erlotinib in combination with berberine in A431 cells.
    Cuan X; Yang X; Zhu W; Zhao Y; Luo R; Huang Y; Wang X; Sheng J
    BMC Pharmacol Toxicol; 2023 May; 24(1):29. PubMed ID: 37170144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual inhibition of EGFR‑VEGF: An effective approach to the treatment of advanced non‑small cell lung cancer with EGFR mutation (Review).
    Wang Q; Zeng A; Zhu M; Song L
    Int J Oncol; 2023 Feb; 62(2):. PubMed ID: 36601768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomarker LEPRE1 induces pelitinib-specific drug responsiveness by regulating ABCG2 expression and tumor transition states in human leukemia and lung cancer.
    Lee AR; Lee S; Shin JY; Kim JY; Moon KS; Jung J
    Sci Rep; 2022 Feb; 12(1):2928. PubMed ID: 35190588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal Sequence and Second-Line Systemic Treatment of Patients with
    Wu CC; Hsu CW; Hsieh MC; Wang JH; Chang MC; Yang CS; Su YC
    J Clin Med; 2021 Nov; 10(21):. PubMed ID: 34768686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LHX6 Affects Erlotinib Resistance and Migration of
    Wang Q; Liao J; He Z; Su Y; Lin D; Xu L; Xu H; Lin J
    Onco Targets Ther; 2020; 13():10983-10994. PubMed ID: 33149613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preparation and identification of an anti-idiotypic antibody antagonist (FG8) for EGFR that shows potential activity against liver cancer cells.
    Wang Y; He F; Zhang H; Cao Y; Zhang Y; Ling Y; Rehati A
    Biotechnol Lett; 2021 Feb; 43(2):369-382. PubMed ID: 33141321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
    Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
    JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGFR-TKIs resistance via EGFR-independent signaling pathways.
    Liu Q; Yu S; Zhao W; Qin S; Chu Q; Wu K
    Mol Cancer; 2018 Feb; 17(1):53. PubMed ID: 29455669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intrapleural targeted therapies (anti-VEGF and anti-EGFR) in the model of malignant pleural effusion.
    Acencio MMP; Puka J; Alvarenga VA; Martins V; de Carvalho MLP; Marchi E; Capelozzi VL; Teixeira LR
    Oncotarget; 2017 Dec; 8(62):105093-105102. PubMed ID: 29285236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
    Puvanenthiran S; Essapen S; Seddon AM; Modjtahedi H
    Int J Oncol; 2016 Nov; 49(5):1825-1838. PubMed ID: 27599579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erlotinib Pretreatment Improves Photodynamic Therapy of Non-Small Cell Lung Carcinoma Xenografts via Multiple Mechanisms.
    Gallagher-Colombo SM; Miller J; Cengel KA; Putt ME; Vinogradov SA; Busch TM
    Cancer Res; 2015 Aug; 75(15):3118-26. PubMed ID: 26054596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nuclear localization of epidermal growth factor receptor (EGFR) in ameloblastomas.
    Pereira NB; do Carmo AC; Diniz MG; Gomez RS; Gomes DA; Gomes CC
    Oncotarget; 2015; 6(12):9679-85. PubMed ID: 25991665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vandetanib in advanced non small cell lung cancer: a promise unfulfilled.
    de Boer RH
    Transl Lung Cancer Res; 2013 Feb; 2(1):E7-9. PubMed ID: 25806216
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.